Nick Ziogas, M.D.
About Nick Ziogas, M.D.
Nick Ziogas, M.D., is the Global Clinical Development Leader for Neuroscience at Bristol Myers Squibb, with extensive experience in advancing drug development programs targeting neurodegenerative diseases.
Company
Nick Ziogas, M.D., currently holds leadership roles at Bristol Myers Squibb. He serves as the Global Clinical Development Leader in Neuroscience and is also the Senior Medical Director for Clinical Development in the same field. His responsibilities include leading programs and initiatives related to neurodegenerative diseases within the company.
Title
Nick Ziogas holds several senior positions within the field of clinical development focused on neuroscience. He is the Global Clinical Development Leader and the Senior Medical Director for Clinical Development at Bristol Myers Squibb. His roles emphasize his expertise in guiding clinical strategies and drug development initiatives.
Education and Expertise
Nick Ziogas has a robust educational background. He earned his Doctor of Medicine (M.D.) from Aristotle University of Thessaloniki. Additionally, he studied Neuroscience and Bioengineering at Stanford University School of Medicine and achieved the Integrated Circuit Cracking CLARITY Workshop. His extensive training includes a Neuropathology fellowship at The Johns Hopkins University School of Medicine, where he further honed his expertise in neuroscience.
Background
Nick Ziogas has a diverse professional background that encapsulates both clinical and research experience in neuroscience. He served as a Physician-Neuroscientist and Neuropathology Fellow at The Johns Hopkins University School of Medicine from 2015 to 2019. Later, he transitioned to Biogen, where he held various roles, including Associate Medical Director, Medical Director, and Global Clinical Development Leader in Alzheimer’s Disease, between 2019 and 2023.
Achievements
Nick Ziogas has made notable contributions to the field of neurodegenerative disease treatment. He has led the clinical development of investigational drugs, advancing drug development programs from pre-clinical research to Phase 3 clinical trials. His leadership in ushering multiple drug development programs through various clinical trial stages demonstrates his significant impact on the biotech industry.